Physician profile
Robert Amrien
NPI 1073570016
$2,182.07
in general payments reported to CMS, 2019-2025
19 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $204 · 2023: $896 · 2024: $372 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $463.48 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $240.07 | 2023-2024 | Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $143.05 | 2025 | |
| Esperion Therapeutics, INC. | $118.41 | 2021-2024 | Nexletol |
| Amgen INC. | $113.87 | 2022-2024 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.32 | 2023-2024 | Xifaxan, Trulance |
| Pfizer INC. | $77.22 | 2023 | |
| Nestle Healthcare Nutrition INC. | $56.28 | 2023 | |
| Glaxosmithkline, LLC. | $47.04 | 2021-2024 | Trelegy Ellipta |
| Lundbeck LLC | $42.46 | 2023 | Rexulti |
| Lilly USA, LLC | $38.37 | 2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $34.62 | 2023 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $21.81 | 2022 | |
| Antares Pharma, INC. | $20.52 | 2024 | Xyosted |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.37 | 2023 | Quviviq |
| Organon LLC | $17.21 | 2023 | Nexplanon |
| Echosens North America, INC. | $13.65 | 2025 | Fibroscan |
| Daiichi Sankyo INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Amrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.